Economic Burden of Antimicrobial Resistance on National Health Budgets: A Cost-of-Illness Study
DOI:
https://doi.org/10.5281/zenodo.22657105Keywords:
antimicrobial resistance, cost of illness, health economics, healthcare expenditure, budget impactAbstract
Background: Antimicrobial resistance (AMR) is increasingly recognized as a direct fiscal threat to national health budgets, as
resistant infections require costlier second-line therapy, longer hospitalization, and greater intensive care utilization than
susceptible infections. Objective: This review synthesizes peer-reviewed cost-of-illness evidence on the economic burden of AMR,
organized around direct medical costs, indirect and productivity costs, and national and macroeconomic budget-impact estimates.
Methods: A narrative synthesis was conducted using PubMed/MEDLINE and Crossref-indexed sources, with every candidate
reference individually verified against publisher or DOI-registry records before inclusion; studies were grouped thematically into
direct-cost, indirect-cost, national cost-of-illness, and macroeconomic burden domains. Findings: Resistant infections are
consistently associated with higher direct medical costs than susceptible infections, driven primarily by excess hospital length of
stay and intensive care use rather than antimicrobial acquisition cost alone, with per-episode excess costs reported across
pathogens including ESKAPE organisms, methicillin-resistant Staphylococcus aureus, and resistant Escherichia coli. Indirect
productivity costs from morbidity and premature mortality are reported far less consistently and, where estimated, are of
comparable or greater magnitude than direct costs. National-level estimates vary by more than an order of magnitude across
studies, but consistently indicate a rising, multi-billion-dollar annual burden in high-income settings, with a disproportionately
high relative burden in lower-income settings despite lower absolute per-episode costs. Conclusions: AMR imposes a measurable
and apparently structural excess burden on national health budgets, but the strongest attributable-cost evidence remains
concentrated in a small number of high-income health systems; standardized, locally derived cost-of-illness studies are needed to
support realistic budget planning elsewhere, including in Central and Eastern Europe.
References
Dadgostar P (2019) Antimicrobial Resistance: Implications and Costs. Infection and Drug Resistance, 12:3903-3910, DOI:10.2147/IDR.S234610.
Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, Knight GM, Robotham JV (2018) Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrobial Resistance & Infection Control, 7:58, DOI:10.1186/s13756-018-0336-y.
de Kraker MEA, Stewardson AJ, Harbarth S (2016) Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLOS Medicine, 13(11):e1002184, DOI:10.1371/journal.pmed.1002184.
Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infectious Diseases, 19(1):56-66, DOI:10.1016/S1473-3099(18)30605-4.
Murray CJL, Ikuta KS, Sharara F, et al. (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 399(10325):629-655, DOI:10.1016/S0140-6736(21)02724-0.
Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A, Palos C, Lopez-Casasnovas G (2020) Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis. PLOS ONE, 15(1):e0227139, DOI:10.1371/journal.pone.0227139.
Zhen X, Lundborg CS, Sun X, Hu X, Dong H (2019) Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. Antimicrobial Resistance & Infection Control, 8:137, DOI:10.1186/s13756-019-0590-7.
Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V (2014) Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrobial Resistance and Infection Control, 3:32, DOI:10.1186/2047-2994-3-32.
Roberts RR, Hota B, Ahmad I, Scott RD 2nd, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA (2009) Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clinical Infectious Diseases, 49(8):1175-1184, DOI:10.1086/605630.
Zhen X, Lundborg CS, Zhang M, Sun X, Li Y, Hu X, Gu S, Gu Y, Wei J, Dong H (2020) Clinical and economic outcomes of the case management of methicillin-resistant Staphylococcus aureus (MRSA) infections: a matched case-control study. BMC Infectious Diseases, 20(1):122, DOI:10.1186/s12879-020-4823-4.
Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, Lesher LJ, Lynfield R (2010) Excess Costs and Utilization Associated with Methicillin Resistance for Patients with Staphylococcus aureus Infection. Infection Control & Hospital Epidemiology, 31(4):365-373, DOI:10.1086/651094.
Naylor NR, Pouwels KB, Hope R, Green N, Henderson KL, Knight GM, Atun R, Robotham JV, Deeny SR (2019) The health and cost burden of antibiotic resistant and susceptible Escherichia coli bacteraemia in the English hospital setting: A national retrospective cohort study. PLOS ONE, 14(9):e0221944, DOI:10.1371/journal.pone.0221944.
Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, Larson EL (2012) Costs of Healthcare- and Community-Associated Infections With Antimicrobial-Resistant Versus Antimicrobial-Susceptible Organisms. Clinical Infectious Diseases, 55(6):807-815, DOI:10.1093/cid/cis552.
Jit M, Ng DHL, Luangasanatip N, Sandmann F, Atkins KE, Robotham JV, Pouwels KB (2020) Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC Medicine, 18:38, DOI:10.1186/s12916-020-1507-2.
Smith R, Coast J (2013) The true cost of antimicrobial resistance. BMJ, 346:f1493, DOI:10.1136/bmj.f1493.
Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, Celhay O, Guerin PJ, Wertheim H, Lubell Y (2018) Enumerating the economic cost of antimicrobial resistance per antibiotic prescribed to inform the evaluation of interventions affecting their use. Antimicrobial Resistance & Infection Control, 7:98, DOI:10.1186/s13756-018-0384-3.
Founou RC, Founou LL, Essack SY (2017) Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. PLOS ONE, 12(12):e0189621, DOI:10.1371/journal.pone.0189621.
Wozniak TM, Barnsbee L, Lee XJ, Pacella RE (2019) Using the best available data to estimate the cost of antimicrobial resistance: a systematic review. Antimicrobial Resistance & Infection Control, 8:26, DOI:10.1186/s13756-019-0472-z.
Nelson RE, Hatfield KM, Wolford H, Samore MH, Scott RD 2nd, Reddy SC, Olubajo B, Paul P, Jernigan JA, Baggs J (2021) National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States. Clinical Infectious Diseases, 72(Suppl 1):S17-S26, DOI:10.1093/cid/ciaa1581.
Thorpe KE, Joski P, Johnston KJ (2018) Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually. Health Affairs, 37(4):662-669, DOI:10.1377/hlthaff.2017.1153.
Gandra S, Barter DM, Laxminarayan R (2014) Economic burden of antibiotic resistance: how much do we really know? Clinical Microbiology and Infection, 20(10):973-980, DOI:10.1111/1469-0691.12798.
Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, Yao G (2023) The economic burden of antibiotic resistance: A systematic review and meta-analysis. PLOS ONE, 18(5):e0285170, DOI:10.1371/journal.pone.0285170.
